Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
BINV Stock Chart & Stats
kr28.25
kr0.20(0.78%)
At close: 4:00 PM EST
kr28.25
kr0.20(0.78%)
Day’s Range― - ―
52-Week Rangekr22.70 - kr42.65
Previous CloseN/A
Volume47.26K
Average Volume (3M)91.72K
Market Cap
$2.18B
Enterprise Valuekr1.48B
Total Cash (Recent Filing)$690.46M
Total Debt (Recent Filing)$10.69M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding65,804,360
10 Day Avg. Volume84,851
30 Day Avg. Volume91,723
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.86
Price to Sales (P/S)56.69
P/FCF Ratio-6.49
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue6.05
Enterprise Value/Gross Profit6.14
Enterprise Value/Ebitda-4.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioInvent International AB News
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr22.70 and its highest was kr42.65 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is $2.18B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Feb 26, 2026 which is in 75 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Oct 29, 2025. The company reported -kr1.964 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.964.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Overvalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.964 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.919%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
Company Description
BioInvent International AB
BioInvent International AB (BINV) is a biotechnology company based in Sweden that focuses on the development of innovative immuno-oncology therapies. The company is primarily engaged in the discovery and development of novel antibodies for the treatment of cancer, leveraging its proprietary technology platform to create product candidates that target various tumor-associated antigens. BioInvent's portfolio includes both preclinical and clinical-stage programs, with a commitment to addressing unmet medical needs in oncology and aiming to improve patient outcomes through its targeted therapies.
BINV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased BioInvent's strategic focus on its lead programs, resulting in positive clinical outcomes and increased sales for the nine-month period. However, the quarter saw decreased sales and increased operating costs, leading to negative financial results.View all SE:BINV earnings summariesTechnical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---